FDA Clears IND for Processa's VT-7208 Phase 2 CSU Trial
PCSA sits 82% above its 52-week low of $1.041 on light trading volume (0.3× avg).
Summary
FDA cleared Processa's IND to start a Phase 2 study of VT-7208 in chronic spontaneous urticaria, a de-risking step for the lead asset, and the company plans Phase 2 studies in food allergy and relapsing multiple sclerosis as well. The company also disclosed a Generian FcRn research/option deal and named Sheila Gujrathi, M.D., Executive Chair. It has roughly $200M from its private placement and guides cash into 2H 2029, which covers planned Phase 2 readouts. This is an execution update following the Vidya merger and $200M PIPE closed in July 2026, with the S-3 resale registration and the November 30 reverse-split vote still pending. The next real test is Phase 2 data in CSU, food allergy or RMS; timelines and endpoints are not specified here.
At the time of this announcement, PCSA was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.04 to $10.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.